Literature DB >> 11134027

The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance.

B Selmi1, J Boretto, J M Navarro, J Sire, S Longhi, C Guerreiro, L Mulard, S Sarfati, B Canard.   

Abstract

The amino acid change V75T in human immunodeficiency virus type 1 reverse transcriptase confers a low level of 2',3'-didehydro-2',3'-dideoxythymidine (stavudine, d4T) resistance in vivo and in vitro. Valine 75 is located at the basis of the fingers subdomain of reverse transcriptase between the template contact point and the nucleotide-binding pocket. V75T reverse transcriptase discriminates 3.6-fold d4T 5'-triphosphate relative to dTTP, as judged by pre-steady state kinetics of incorporation of a single nucleotide into DNA. In addition, V75T increases the DNA polymerization rate up to 5-fold by facilitating translocation along nucleic acid single-stranded templates. V75T also increases the reverse transcriptase-mediated repair of the d4TMP-terminated DNA by pyrophosphate but not by ATP. The V75T/Y146F double substitution partially suppressed both increases in rate of polymerization and pyrophosphorolysis, indicating that the hydroxyl group of Thr-75 interacts with that of Tyr-146. V75T recombinant virus was 3-4-fold d4T-resistant and 3-fold resistant to phosphonoformic acid relative to wild type, confirming that the pyrophosphate traffic is affected in V75T reverse transcriptase. Thus, in addition to nucleotide selectivity V75T defines a type of amino acid change conferring resistance to nucleoside analogues that links translocation rate to the traffic of pyrophosphate at the reverse transcriptase active site.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11134027     DOI: 10.1074/jbc.M009837200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

2.  Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.

Authors:  George L Melikian; Soo-Yon Rhee; Jonathan Taylor; W Jeffrey Fessel; David Kaufman; William Towner; Paolo V Troia-Cancio; Andrew Zolopa; Gregory K Robbins; Ron Kagan; Dennis Israelski; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

Review 3.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

4.  Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.

Authors:  Nicolas Sluis-Cremer; Chih-Wei Sheen; Shannon Zelina; Pedro S Argoti Torres; Urvi M Parikh; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

5.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

6.  Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase.

Authors:  Egor P Tchesnokov; Aleksandr Obikhod; Ivana Massud; Andrea Lisco; Christophe Vanpouille; Beda Brichacek; Jan Balzarini; Christopher McGuigan; Marco Derudas; Leonid Margolis; Raymond F Schinazi; Matthias Götte
Journal:  J Biol Chem       Date:  2009-06-09       Impact factor: 5.157

7.  Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination.

Authors:  Tania Matamoros; María Nevot; Miguel Angel Martínez; Luis Menéndez-Arias
Journal:  J Biol Chem       Date:  2009-09-29       Impact factor: 5.157

8.  Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4'-ethynyl stavudine triphosphate.

Authors:  Guangwei Yang; Jimin Wang; Yao Cheng; Ginger E Dutschman; Hiromichi Tanaka; Masanori Baba; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

Review 9.  Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.

Authors:  Stefan G Sarafianos; Bruno Marchand; Kalyan Das; Daniel M Himmel; Michael A Parniak; Stephen H Hughes; Eddy Arnold
Journal:  J Mol Biol       Date:  2008-11-03       Impact factor: 5.469

10.  Synthesis and substrate properties towards HIV-1 reverse transcriptase of new diphosphate analogues of 9-[(2-phosphonomethoxy)ethyl]adenine.

Authors:  Wolfgang Hg Laux; Stéphane Priet; Karine Alvarez; Suzanne Peyrottes; Christian Périgaud
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.